WO2023023506A1

WO2023023506A1 - Composition and method for inhibition of scaling in high- salinity, temperature, and pressure applications

Info

Publication number: WO2023023506A1
Application number: PCT/US2022/075005
Authority: WO
Inventors: Seethalakshmi Suresh; Yogitha G.; Chaitra M.N.
Original assignee: Bl Technologies, Inc.
Priority date: 2021-08-17
Filing date: 2022-08-16
Publication date: 2023-02-23
Also published as: EP4388057A1; AR126804A1

Abstract

A synergistic anti-scaling composition, the composition having a scale inhibitor; and a compatibility aid. A synergistic anti-scaling composition, the composition having a scale inhibitor combination, the combination providing (i) a polymer composition, and (ii) a phosphonate composition. A synergistic anti-scaling composition, the composition having a scale inhibitor combination providing (i) a polymer composition, and (ii) a phosphonate composition and a compatibility aid. A method for inhibiting scale formation, the method providing a synergistic anti-scaling composition, the composition having a scale inhibitor, and a compatibility aid; and providing the synergistic anti-scaling composition to an aqueous scaling environment.

Description

COMPOSITION AND METHOD FOR INHIBITION OF SCALING IN HIGH- SALINITY, TEMPERATURE, AND PRESSURE APPLICATIONS

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the priority benefit of Indian Provisional Patent Application Serial No. IN 202111037325 filed August 17, 2021, the entirety of which is incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The disclosed technology provides treatment compositions and methods to inhibit the formation and deposition of mineral scales, and more specifically, treatment compositions and methods to inhibit the formation and deposition of mineral scales in high salinity, high temperature, and high-pressure environments.

BACKGROUND OF THE INVENTION

[0003] Energy production exposes systems to high concentrations of brine (i.e. salinity up to ~300,000ppm) under conditions of high pressure (-5000 psi) and temperatures (~250°C). In such systems, scaling (i.e. the deposition of mineral solids on the surfaces of the energy production or transfer systems) can lead to blockages of these systems or inefficiencies in the functioning of these systems.

[0004] For example, the formation of inorganic (i.e. sparingly soluble salts from aqueous brines during geothermal energy production) leads to scaling. The damage caused by scale is one of the biggest challenges encountered by geothermal industries. Scale deposition damages the downhole equipment of geothermal wells and moreover decreases in flow rate leads to a loss in production. In geothermal systems, various sulfide-based scales, for example, metal sulfides such as iron sulfide (FeS), zinc sulfide (ZnS) and lead sulfide (PbS), can form problematic depositions.

[0005] Similarly, the extraction of oil and gas from subterranean reservoirs subjects its operating systems to high temperatures and pressures thus leads to supersaturated conditions wherever the mixing of the incompatible types of water takes place. In these environments, temperature or pressure changes are severe enough to produce a supersaturated solution, and thus scaling occurs. The deposited scale adhere on the surfaces of the producing well tubing and on parts of water handling equipment, where it builds up. In time, this scaling leads to problems in reservoirs, pumps, valves and topside facilities. The rapid increase of the mineral deposits leads to inevitable damage of the equipment parts. As a consequence, suspension of production activities is necessary for the reparation or replacement of damaged parts.

[0006] One example of such an environment is found in “pre-salt” formations. “Pre-Salt” describes where the reservoir rock is located below a layer of salt, which can exceed 2,000m in thickness in some areas. Considering that the water depth can reach over 2,000m, the pre-salt reservoir can be located over 7,000m depth.

[0007] This specific environment describes where an oil reservoir is located below a layer of salt, where the wells drilled to access the hydrocarbon formation are under several kilometers of ocean, and further, where the hydrocarbon bearing formations are located several thousand meters beneath the seabed. Thus, the crude from these reservoirs must be transited though several kilometers of piping to reach the initial processing and/or storage facilities. Scaling is particularly problematic in such “pre-salt” environments due to extreme pressure and temperature changes which the crude hydrocarbons and associated mineral laden brines undergo in their transit from the deep formations to the platform or processing centers which are located on the surface.

[0008] As the quest for new oil and gas formations to develop drives exploration into ever more challenging environments, ensuring flow (flow assurances) of the wells becomes critical to the economic operation of these oil and gas fields. Thus, the development of new formulations and products that will work for the high TDS (total dissolved solids) water composition (z.e. having different ionic strength), multiple scales, specific pH range requirements for the product and water associated with the product, the chemical compatibility range and the expected dosage is needed to meet these production challenges.

[0009] The disclosed technology is also applicable for scale inhibition in highly acidic aqueous systems like those found in mining applications, where process waters have high concentrations of hardness, sulfates, chlorides, organics, and salts. The current disclosed synergistic composition helps to treat these processes for the inhibition of and/or removal of scale deposits, such as calcium sulfate scale/calcium carbonate, by adding the scale control agent to a highly acidic system.

[0010] Further, membrane applications, such as Nanofiltration (NF), Reverse Osmosis (RO), Electrodialysis (ED) and Membrane Distillation (MD), have been used for the treatment of brackish (ground and surface) water, seawater and treated wastewater. During the concentration process, the solubility limits of sparingly soluble salts, such as sulfates of calcium, barium and strontium; carbonates of calcium, magnesium, barium; and phosphates of calcium, are exceeded, resulting in scale formation on a membrane surface as well as in the system. Membrane scaling results in the loss of permeate flux through the membrane. The disclosed synergistic composition can be successfully used to inhibit various scale formation.

[0011] Thus, what is needed in the art are treatments and methods for inhibiting the scale formation in an aqueous scaling environment, as well as dissolving and removing already existing scales that are present in extreme conditions of temperatures and pressures.

SUMMARY OF THE INVENTION

[0012] The disclosed technology provides for synergistic anti-scaling composition. In one aspect of the disclosed technology, the anti-scaling composition comprises a scale inhibitor, and a compatibility aid.

[0013] In some embodiments, the scale inhibitor comprises an organophosphoric acid, organophosphonic acid, a phosphonate-based compound, polymeric phosphonate, polycarboxylic acids, a carboxylic sulphonated copolymer, and/or a carboxylic sulphonated terpolymer. In some embodiments, the scale inhibitor comprises an organopolyphosphorous acid, an organopolyphosphonic acid, an organopolyphosphoric acid, and/or an organopolyphosphorous acid. In some embodiments, the scale inhibitor comprises a diphosphonate, a triphosphonate, a tetraphosphonate, a pentaphosphonate, and/or a hexaphosphonate or derivatives thereof. In some embodiments, the scale inhibitor comprises a polyamino polyether methylene phosphonic acid, a (hydroxyethyl)imino]bis(methylene)]-bisphosphonic acid, or a combination thereof. In some embodiments, the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer.

[0014] In some embodiments, the compatibility aid comprises a chelating agent, or salt thereof. In some embodiments, the compatibility aid comprises an aminopoly carboxylic acid, or a salt thereof. In some embodiments, the compatibility aid comprises a diethylenetriaminepentaacetic acid, or a salt thereof.

[0015] In some embodiments, the synergistic anti-scaling composition further comprises an inorganic base. In some embodiments, the inorganic base is a hydroxide base.

[0016] In another aspect of the disclosed technology, a synergistic antiscaling composition comprises a scale inhibitor combination, the combination comprising (i) a polymer composition, and (ii) a phosphonate composition.

[0017] In some embodiments, the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer. In some embodiments, the sulphonated ter-polymer is acrylic acid based or maleic acid based. In some embodiments, the phosphonate composition comprises hydroxy ethyl)imino]bis(methylene)]-bisphosphonic acid.

[0018] In some embodiments, the ratio of polymer composition to phosphonate composition is in the range of about 1:50 to about 50:1. In some embodiments, the ratio of polymer composition to phosphonate composition is in the range of about 1:10 to about 9:1. It should be understood that this ratio varies based on the type of scales present.

[0019] In another aspect of the disclosed technology, a synergistic antiscaling composition comprises a scale inhibitor combination, the combination comprising (i) a polymer composition; and (ii) a phosphonate composition, and a compatibility aid.

[0020] In some embodiments, the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer. In some embodiments, the ratio of polymer composition to phosphonate composition is in the range of about 1:50 to about 50:1. In some embodiments, the ratio of polymer composition to phosphonate composition is in the range of about 1 : 10 to about 9: 1. [0021] In some embodiments, the compatibility aid comprises (i) a chelating agent, or salt thereof, (ii) an aminopolycarboxylic acid, or a salt thereof, or (iii) a diethylenetriaminepentaacetic acid, or a salt thereof.

[0022] In some embodiments, the synergistic anti-scaling composition exhibits a coil ID of about 0.5-0.8mm. In some embodiments, the synergistic antiscaling composition exhibits a coil ID of about 0.5-0.55mm.

[0023] In another aspect of the disclosed technology, a method for inhibiting scale formation is provided. The method comprising providing a synergistic antiscaling composition, the composition comprising: a scale inhibitor; and a compatibility aid; and providing the synergistic anti-scaling composition to an aqueous scaling environment.

[0024] In some embodiments, the scale inhibitor comprises an organophosphoric acid, a phosphonic acid, a phosphonate-based compound, or a carboxylic sulphonated copolymer.

[0025] In some embodiments, the compatibility aid comprises a chelating polyacid or salt thereof.

[0026] In some embodiments, the aqueous scaling environment is a hydrocarbon producing well, a geothermal well, mining, or membrane applications. In some embodiments, about 10-500 ppm of the anti-scaling composition is added to the aqueous scaling environment. In some embodiments, providing the scale inhibitor composition with the aqueous scaling environment occurs at a temperature from about 20 °C to about 250 °C. In some embodiments, the aqueous scaling environment comprises a pressure of about 15 psi to 5000 psi.

[0027] In some embodiments, the aqueous scaling environment comprises a calcium level of about 100 ppm to about 20,000 ppm. In some embodiments, the aqueous scaling environment comprises a salinity level of about 100 ppm to about 3,00,000 ppm. In some embodiments, the aqueous scaling environment comprises a temperature up to about 150°C, and a salinity level up to about 300,000 ppm.

[0028] In some embodiments, the aqueous scaling environment comprises calcite, calcium sulfate, celestite, barite, iron carbonate, and/or combinations thereof.

[0029] In some embodiments, the aqueous scaling environment comprises a salinity brine having a temperature of about 0°C to about 150°C. In some embodiments, the aqueous scaling environment prone to scaling has a saturation index from about 1.5 SI to about 3.0 SI. In some embodiments, the anti-scaling composition further comprises an inorganic base.

[0030] In some embodiments, the ratio of scale inhibitor to compatibility aid to inorganic base is about 2: 1:1 to about 50:45:5.

[0031] In some embodiments, the scale inhibitor comprises about 2% to about 75% by weight of the composition. In some embodiments, the compatibility aid comprises about 0.5% to about 45% by weight of the composition.

BRIEF DESCRIPTION OF THE DRAWINGS

[0032] These and other features of the disclosed technology, and the advantages, are illustrated specifically in embodiments now to be described, by way of example, with reference to the accompanying diagrammatic drawings, in which:

[0033] FIG. 1 is a table of results of illustrative embodiments of the disclosed technology;

[0034] FIGS. 2A-2B provide experimental results of an illustrative embodiment of the disclosed technology;

[0035] FIGS. 3A-3B provide experimental results of an illustrative embodiment of the disclosed technology;

[0036] FIGS. 4A-4B provide experimental results of an illustrative embodiment of the disclosed technology;

[0037] FIG. 5 is a graph of experimental results of an illustrative embodiment of the disclosed technology;

[0038] FIG. 6 is a graph of experimental results of an illustrative embodiment of the disclosed technology;

[0039] FIG. 7 provides experimental results of an illustrative embodiment of the disclosed technology;

[0040] FIGS. 8A-8C provide graphs of experimental results of an illustrative embodiment of the disclosed technology;

[0041] FIG. 9 provides experimental results of an illustrative embodiment of the disclosed technology; and

[0042] FIG. 10 provides experimental results of an illustrative embodiment of the disclosed technology. DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

[0043] The disclosed technology generally provides treatment compositions and methods to inhibit the formation and deposition of mineral scales, and more specifically, treatment compositions and methods to inhibit the formation and deposition of mineral scales in high temperature and high-pressure environments.

[0044] The anti-scaling composition as described herein provides for the inhibition and prevention of scale formation of systems operating in a high pressure and a high concentration of dissolved salts. Such scale formation may include, but is not limited to, scaling that is subject to the deposition of multiple scales, (e.g. silica, calcium sulfate, calcite, barite, and celestite scales).

[0045] It was surprisingly discovered that the anti-scaling composition as described herein provides a synergistic effect, where the anti-scaling composition removes already formed or difficult to remove scaling, and in some cases, prevents new scaling present in systems exposed to high concentrations of brine under conditions of high pressure and temperatures (which alters the scaling potential of multiple scales). It was shown that the anti-scaling compositions as described herein significantly aided in achieving a passing compatibility requirement rating, as well as increased anti-scaling performance due to the synergy of components present.

[0046] Due to the elevated temperatures and pressures, the present technology prevents scale formation in environments having a high concentration of total dissolved solids (TDS), wherein TDS is a measurement of soluble salt concentration in a volume of water. For example, such environments may include, but are not limited to, sub-sea oil and gas fields, geothermal, membrane, evaporator, mining, on land oil and gas fields, steam-assisted gravity drainage (SAGD), and fracking applications.

[0047] The present technology provides for a synergistic anti-scaling composition, wherein the composition comprises a scale inhibitor; and a compatibility aid.

[0048] The synergistic anti-scaling composition comprises a scale inhibitor. The scale inhibitor as described herein acts as a nucleation inhibitor, as well as a crystal growth inhibitor. It is believed that the anti-scaling composition provides a synergistic effect due to the specific combination of a nucleation inhibitor and a crystal growth/dispersant mechanism provided by the scale inhibitor.

[0049] In some embodiments, the scale inhibitor comprises an organophosphoric acid, organophosphonic acid, a phosphonate-based compound, polymeric phosphonate, polycarboxylic acids, a carboxylic sulphonated copolymer, and/or a carboxylic sulphonated terpolymer.

[0050] In some embodiments, the scale inhibitor comprises an organopolyphosphorous acid, an organopolyphosphonic acid, an organopolyphosphoric acid, and/or an organopolyphosphorous acid.

[0051] In some embodiments, the scale inhibitor comprises a diphosphonate, a triphosphonate, a tetraphosphonate, a pentaphosphonate, and/or a hexaphosphonate or derivatives thereof. It is believed that the molecular weight and distance between the phosphonates aid in the performance of the scale inhibitor.

[0052] In some embodiments, the scale inhibitor comprises a polyamino polyether methylene phosphonic acid, a (hydroxyethyl)imino]bis(methylene)]- bisphosphonic acid, or a combination thereof. It is believed that ethylene oxide and hydroxy ethyl amino groups contribute to the synergy of the present technology by aiding in compatibility.

[0053] In some embodiments, the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer. In some embodiments, the terpolymer acts as a crystal growth modifier.

[0054] The synergistic anti-scaling composition further comprises a compatibility aid. The compatibility aid as described herein helps to chelate with salts and keeps them in dissolved form. As used herein, the term “compatibility aid” is meant to describe a chemical additive that provides stability and performance to the formulation at the expected pressure and temperature ranges. For reference, brine compatibility (i.e. compatibility with high TDS/Ca/Mg brines) issues are experienced when solid deposition or formation damages result due to the interaction of a scale inhibitor with the brine chemistry. As such, a scale inhibitor with problems of brine compatibility could instead eventually cause a scale related issue that it would be supposed to inhibit. Therefore, brine compatibility is frequently determined by pass/fail criteria that is considered prior to performance tests. In some embodiments, the compatibility aid helps to keep the formulation stable with the high TDS brine and prevents formation damage.

[0055] In some embodiments, the compatibility aid comprises a chelating agent, or salt thereof. In some embodiments, the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), diethylene triamine penta acetic acid (DTP A), or citric acid. The chelating agent as described herein will bind with metal ions and will keep the salts in solution.

[0056] In some embodiments, the compatibility aid comprises an aminopoly carboxylic acid, or a salt thereof. In some embodiments, the compatibility aid comprises a diethylenetriaminepentaacetic acid, or a salt thereof.

[0057] In some embodiments, the synergistic anti-scaling composition further comprises an inorganic base. The inorganic based is provided for pH adjustment. In some embodiments, the inorganic base is a hydroxide base.

[0058] In yet another aspect of the disclosed technology, a method for inhibiting the scale formation is provided. The method comprises providing a synergistic anti-scaling composition and providing the synergistic anti-scaling composition to an aqueous scaling environment.

[0059] The synergistic anti-scaling composition of the present method comprises a scale inhibitor; and a compatibility aid. It should be understood that the scale inhibitor, and compatibility aid can be added by any conventional means known in the art to obtain the anti-scaling composition of the present technology.

[0060] In some embodiments, the scale inhibitor comprises an organophosphoric acid, a phosphonic acid, a phosphonate-based compound, or a carboxylic sulphonated copolymer.

[0061] In some embodiments, the scale inhibitor comprises about 2% to about 75% by weight of the composition. In other embodiments, the scale inhibitor comprises about 2% to about 60% by weight of the composition, and in other embodiments, the scale inhibitor comprises about 10% to about 45% by weight of the composition.

[0062] The anti-scaling composition of the present method comprises a chelating polyacid or salt thereof. In some embodiments, the chelating polyacid or salt thereof comprises ethylenediaminetetraacetic acid (EDTA), hydroxyethyl ethylenediamine triacetic acid (HEDTA), or N,N-Dicarboxymethyl glutamic acid tetrasodium salt (GLDA).

[0063] In some embodiments, the compatibility aid of the present method comprises about 0.5% to about 45% by weight of the composition. In other embodiments, the compatibility aid comprises about 1% to about 20% by weight of the composition.

[0064] In some embodiments, the anti-scaling composition of the present method further comprises an inorganic base. In some embodiments, the inorganic base comprises NaOH or KOH.

[0065] In some embodiments, the ratio of scale inhibitor to compatibility aid to inorganic base is about 2: 1:1 to about 50:45:5.

[0066] The method further comprises providing the synergistic anti-scaling composition to an aqueous scaling environment. In some embodiments, the synergistic anti-scaling composition is injected continuously into the aqueous scaling environment. The aqueous scaling environment as described herein includes those environments having a high salinity (-200-200,000 ppm TDS), high pH (-6- 8.5), and multiple scale environment.

[0067] In some embodiments, about 5-500 ppm of the anti-scaling composition is added to the aqueous scaling environment. In other embodiments, about 10-500 ppm of the anti-scaling composition is added to the aqueous scaling environment, and in other embodiments, about 5-200 ppm of the anti-scaling composition is added to the aqueous scaling environment.

[0068] In some embodiments, the scale inhibitor composition is provided to the aqueous environment at a temperature from about 20°C to about 250°C. In other embodiments, the scale inhibitor composition is provided to the aqueous environment at a temperature from about 20°C to about 150°C.

[0069] In some embodiments, the aqueous scaling environment is a hydrocarbon-producing well or a geothermal well. It should be understood that a hydrocarbon-producing well platform penetrates a pre-salt oil deposit (i.e. penetrates into a pre-salt layer).

[0070] In some embodiments, the aqueous scaling environment comprises a pressure of about 15 psi to 5000 psi. [0071] In some embodiments, the aqueous scaling environment comprises a calcium level of about 100 ppm to about 20,000 ppm, and in other embodiments, about 100 ppm to about 16,000 ppm.

[0072] In some embodiments, the aqueous scaling environment comprises a salinity level of about 100 ppm to about 500,000 ppm, and in other embodiments, about 100 ppm to about 300,000 ppm.

[0073] In some embodiments, the aqueous scaling environment comprises a temperature up to about 130 °C, and a salinity level up to about 150,000 ppm.

[0074] In some embodiments, the aqueous scaling environment comprises calcite, calcium sulfate, celestite, barite, iron carbonate, and/or combinations thereof.

[0075] In some embodiments, the aqueous scaling environment comprises of high salinity brine having a temperature of about 0°C to about 250°C, and in other embodiments, 0°C to about 150°C.

[0076] In some embodiments, the aqueous scaling environment has a saturation index (SI) from about 1.5 SI to about 3.0 SI. It should be understood that the saturation index (SI) describes the index for determining whether water will tend to dissolve or precipitate a particular mineral and will indicate the severity of the scaling potential.

EXAMPLES

[0077] The present technology will be further described in the following examples, which should be viewed as being illustrative and should not be construed to narrow the scope of the disclosed technology or limit the scope to any particular embodiments.

[0078] FIG. 1 exhibits the synergistic effect of the treatment compositions and methods as described herein (* AMP -Aminomethylene Phosphonate; **(Homo or copolymer or Terpolymer); **** Alkylpolycarboxylate). The product as disclosed herein was at pH 4-7. The compatibility range shown in FIG. 1 was 300,000ppm brine compatibility, which was achieved only in the presence of the disclosed synergistic combination according to the present technology. As shown in FIG. 1, in a tube blocking experiment, the synergistic anti-scaling composition exhibited a coil ID of about 0.5-0.8mm. [0079] Table 1 provides the water formulation conditions of the compositions provided in FIG. 1.

TABLE 1

[0080] FIGS. 2A-2B include the results of Scenario #1. As shown, the composition of FIG. 2A failed to meet the compatibility requirement, while the composition of FIG. 2B provided a synergistic effect and thus passed the compatibility requirement.

[0081] FIGS. 3A-3B include the results of Scenario #2. From visual observation, FIG. 3A showed precipitate, and FIG. 3B is clear after the compatibility test; thus passing the compatibility requirement. As shown, the composition of FIG. 3A failed to meet the compatibility requirement at 2,500 ppm and 5000 ppm, while the composition of FIG. 3B provided a synergistic effect and thus passed the compatibility requirement.

[0082] FIGS. 4A-4B include the results of Scenario #3. FIGS. 4A-4B prove how the synergistic effect of the composition described herein aided in brine compatibility as well as performance. From visual observation, FIG. 4A shows precipitate, while FIG. 4B is clear after the compatibility test; thus passing the compatibility requirement. As shown, FIG. 4A failed to meet the compatibility requirement, while the compositions of FIGS. 4B-provided a synergistic effect and thus passed the compatibility requirement.

[0083] FIG. 5 further provides a comparison of the performance of Scenario #3.

[0084] FIG. 6 further provides a comparison of the performance of Scenario #2.

[0085] FIG. 7 provides additional results related to Scenario #2, where the compatibility tested was 130°C for 20 hours at a dosage of 50,000ppm in order to determine the compatibility dosage limit. As shown, FIG. 7 passed the compatibility requirement at 50,000 ppm.

[0086] Table 2 provides the results of the scaling inhibition performance provided by the present technology as described herein.

[0087] FIGS. 8A-8C and FIG. 9 provide the results from a Dynamic Scale Loop (DSL) performance test of Scenario #4 as provided in TABLE 2, showing the synergistic effect of the present technology as described herein.

[0088] FIG. 10 provides the results related to Scenario #4 and #5 as provided in FIG. 1.

[0089] TABLE 3 provides the compatibility results provided by the present technology as described herein.

[0090] Further, the synergistic effect of the present technology can be measured with the Dynamic Scale Loop (DSL) coil ID performance obtained. As one skilled in the art would readily know and understand, typical DSL coil ID are ~0.7-0.8mm. With the increasing severity of pre-salt conditions, Oil & Gas demands the need of product performing at 0.5-0.55mm coil ID. The present technology as described herein was able to perform at 0.51mm coil ID with a flat curve for 120minutes without increasing the DP.

[0091] While embodiments of the disclosed technology have been described, it should be understood that the present disclosure is not so limited and modifications may be made without departing from the disclosed technology. The scope of the disclosed technology is defined by the appended claims, and all devices, processes, and methods that come within the meaning of the claims, either literally or by equivalence, are intended to be embraced therein.

Claims

CLAIMS A synergistic anti-scaling composition, the composition comprising: a. a scale inhibitor; and b. a compatibility aid. The synergistic anti-scaling composition of Claim 1, wherein the scale inhibitor comprises an organophosphoric acid, organophosphonic acid, a phosphonate-based compound, polymeric phosphonate, polycarboxylic acids, a carboxylic sulphonated copolymer, and/or a carboxylic sulphonated terpolymer. The synergistic anti-scaling composition of Claim 1, wherein the scale inhibitor comprises an organopolyphosphorous acid, an organopolyphosphonic acid, an organopoly phosphoric acid, and/or an organopolyphosphorous acid. The synergistic anti-scaling composition of Claim 1, wherein the scale inhibitor comprises a diphosphonate, a triphosphonate, a tetraphosphonate, a pentaphosphonate, and/or a hexaphosphonate or derivatives thereof. The synergistic anti-scaling composition of Claim 1, wherein the scale inhibitor comprises a polyamino polyether methylene phosphonic acid, a (hydroxyethyl)imino]bis(methylene)]-bisphosphonic acid, or a combination thereof. The synergistic anti-scaling composition of Claim 1, wherein the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer. The synergistic anti-scaling composition of Claim 1, wherein the compatibility aid comprises a chelating agent, or salt thereof. The synergistic anti-scaling composition of Claim 1, wherein the compatibility aid comprises an aminopoly carboxylic acid, or a salt thereof. The synergistic anti-scaling composition of Claim 1, wherein the compatibility aid comprises a diethylenetriaminepentaacetic acid, or a salt thereof. The synergistic anti-scaling composition of Claim 1, further comprising an inorganic base. The synergistic anti-scaling composition of Claim 10, wherein the inorganic base is a hydroxide base. A synergistic anti-scaling composition, the composition comprising: a. a scale inhibitor combination, the combination comprising

(i) a polymer composition, and (ii) a phosphonate composition. The synergistic anti-scaling composition of Claim 12, wherein the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer. The synergistic anti-scaling composition of Claim 13, wherein the sulphonated ter-polymer is acrylic acid based or maleic acid based. The synergistic anti-scaling composition of Claim 12, wherein the phosphonate composition comprises hydroxyethyl)imino]bis(methylene)]- bisphosphonic acid. The synergistic anti-scaling composition of Claim 12, wherein the ratio of polymer composition to phosphonate composition is in the range of about 1:50 to about 50:1. 17 The synergistic anti-scaling composition of Claim 16, wherein the ratio of polymer composition to phosphonate composition is in the range of about 1:10 to about 9:1. A synergistic anti-scaling composition, the composition comprising: a. a scale inhibitor combination comprising (i) a polymer composition, and (ii) a phosphonate composition; and b. a compatibility aid. The synergistic anti-scaling composition of Claim 18, wherein the scale inhibitor comprises a sulphonated ter-polymer, or a carboxylic-sulfonated copolymer. The synergistic anti-scaling composition of Claim 18, wherein the ratio of polymer composition to phosphonate composition is in the range of about 1:50 to about 50:1. The synergistic anti-scaling composition of Claim 20, wherein the ratio of polymer composition to phosphonate composition is in the range of about 1:10 to about 9:1. The synergistic anti-scaling composition of Claim 18, wherein the compatibility aid comprises (i) a chelating agent, or salt thereof, (ii) an aminopolycarboxylic acid, or a salt thereof, or (iii) a diethylenetriaminepentaacetic acid, or a salt thereof. The synergistic anti-scaling composition of Claim 18, wherein the synergistic anti-scaling composition exhibits a coil ID of about 0.5-0.8mm. The synergistic anti-scaling composition of Claim 23, wherein the synergistic anti-scaling composition exhibits a coil ID of about 0.5-0.55mm. A method for inhibiting scale formation, the method comprising: a. providing a synergistic anti-scaling composition, the composition comprising: i. a scale inhibitor, and ii. a compatibility aid; and b. providing the synergistic anti-scaling composition to an aqueous scaling environment. The method of Claim 25, wherein the scale inhibitor comprises an organophosphoric acid, a phosphonic acid, a phosphonate-based compound, or a carboxylic sulphonated copolymer. The method of Claim 25, wherein the compatibility aid comprises a chelating polyacid or salt thereof. The method of Claim 25, where the aqueous scaling environment is a hydrocarbon producing well, a geothermal well, mining, or membrane application. The method of Claim 25, wherein about 10-500 ppm of the antiscaling composition is added to the aqueous scaling environment. The method of Claim 25, wherein providing the scale inhibitor composition with the aqueous scaling environment occurs at a temperature from about 20 °C to about 250 °C. The method as recited in Claim 25, wherein the aqueous scaling environment comprises a pressure of about 15 psi to 5000 psi. The method as recited in Claim 25, wherein the aqueous scaling environment comprises a calcium level of about 100 ppm to about 20,000 ppm. The method as recited in Claim 25, wherein the aqueous scaling environment comprises a salinity level of about 100 ppm to about 3,00,000 ppm. 19 The method as recited in Claim 25, wherein the aqueous scaling environment comprises a temperature up to about 150°C, and a salinity level up to about 300,000 ppm. The method as recited in Claim 25, wherein the aqueous scaling environment comprises calcite, calcium sulfate, celestite, barite, iron carbonate, and/or combinations thereof. The method as recited in Claim 25, wherein the aqueous scaling environment comprises a salinity brine having a temperature of about 0 °C to about 150 °C. The method as recited in Claim 25, wherein the aqueous scaling environment prone to scaling has a saturation index from about 1.5 SI to about 3.0 SI. The method as recited in Claim 25, wherein the anti-scaling composition further comprises an inorganic base. The method as recited in Claim 38, wherein the ratio of scale inhibitor to compatibility aid to inorganic base is about 2:1:1 to about 50:45:5. The method as recited in Claim 25, wherein the scale inhibitor comprises about 2% to about 75% by weight of the composition. The method as recited in Claim 25, wherein the compatibility aid comprises about 0.5% to about 45% by weight of the composition.